{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:43:15Z","timestamp":1793911395826,"version":"4.8.0"},"reference-count":167,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009881","name":"Juvenile Diabetes Research Foundation Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007885","name":"European Association for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007885","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.yjmcc.2025.06.013","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T18:29:52Z","timestamp":1751740192000},"page":"55-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management"],"prefix":"10.1016","volume":"206","author":[{"given":"David","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sindone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.H.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlheinz","family":"Peter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia J.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0005","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0015","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of Diabetes. A Consensus Report of the American Diabetes Association","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0020","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"issue":"24","key":"10.1016\/j.yjmcc.2025.06.013_bb0025","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1161\/CIRCULATIONAHA.118.034986","article-title":"Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without Diabetes mellitus","volume":"138","author":"McAllister","year":"2018","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0030","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.2337\/dc12-2455","article-title":"Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes","volume":"36","author":"Constantino","year":"2013","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.yjmcc.2025.06.013_bb0035","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0040","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0045","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2018.01514","article-title":"Diabetic cardiomyopathy: current and future therapies, Beyond Glycemic Control","volume":"9","author":"Borghetti","year":"2018","journal-title":"Front. Physiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0050","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/heartjnl-2016-310342","article-title":"Diabetic cardiomyopathy","volume":"105","author":"Lee","year":"2019","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.06.013_bb0055","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ejhf.822","article-title":"Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland","volume":"19","author":"Mamas","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"10244","key":"10.1016\/j.yjmcc.2025.06.013_bb0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"issue":"9786","key":"10.1016\/j.yjmcc.2025.06.013_bb0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(11)60471-6","article-title":"Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study","volume":"378","author":"Lind","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.yjmcc.2025.06.013_bb0070","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.yjmcc.2025.06.013_bb0075","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2337\/dc15-0991","article-title":"An inverse relationship between age of type 2 Diabetes onset and complication risk and mortality: the impact of youth-onset type 2 Diabetes","volume":"39","author":"Al-Saeed","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12933-021-01328-0","article-title":"A cross sectional study to compare cardiac structure and diastolic function in adolescents and young adults with youth-onset type 1 and type 2 diabetes: the SEARCH for Diabetes in youth study","volume":"20","author":"Shah","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00592-013-0455-0","article-title":"Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort study","volume":"50","author":"Konduracka","year":"2013","journal-title":"Acta Diabetol."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0090","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1007\/s00125-023-06068-2","article-title":"Epidemiology of heart failure in diabetes: a disease in disguise","volume":"67","author":"Hoek","year":"2024","journal-title":"Diabetologia"},{"issue":"19","key":"10.1016\/j.yjmcc.2025.06.013_bb0095","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1161\/01.CIR.101.19.2271","article-title":"Impact of diabetes on cardiac structure and function: the strong heart study","volume":"101","author":"Devereux","year":"2000","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.amjcard.2008.02.082","article-title":"Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population","volume":"101","author":"Eguchi","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.658726","article-title":"Women with Diabetes are at increased relative risk of heart failure compared to men: insights from UK biobank","volume":"8","author":"Chadalavada","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/EJE-18-0792","article-title":"Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis","volume":"180","author":"Xu","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0115","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3389\/fphys.2018.00453","article-title":"Diabetic cardiomyopathy: impact of biological sex on disease development and molecular signatures","volume":"9","author":"Toedebusch","year":"2018","journal-title":"Front. Physiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0120","doi-asserted-by":"crossref","first-page":"11664","DOI":"10.1038\/s41598-021-91170-x","article-title":"Sex-specific impact of diabetes mellitus on left ventricular systolic function and prognosis in heart failure","volume":"11","author":"Kwak","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0125","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12933-024-02360-6","article-title":"Sex differences in the diagnostic algorithm of screening for heart failure by symptoms and NT-proBNP in patients with type 2 diabetes","volume":"23","author":"Hofer-Zeni","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0130","article-title":"The diabetic cardiomyopathy: the contributing pathophysiological mechanisms","volume":"8","author":"Salvatore","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.06.013_bb0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","article-title":"Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence","volume":"17","author":"Tan","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10741-013-9374-y","article-title":"Advanced glycation end products: role in pathology of diabetic cardiomyopathy","volume":"19","author":"Bodiga","year":"2014","journal-title":"Heart Fail. Rev."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0145","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1194\/jlr.M400442-JLR200","article-title":"Chemical modification of proteins during peroxidation of phospholipids","volume":"46","author":"Januszewski","year":"2005","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0150","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s13300-017-0333-9","article-title":"A review of insulin resistance in type 1 Diabetes: is there a place for adjunctive metformin?","volume":"9","author":"Priya","year":"2018","journal-title":"Diabetes Ther"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0155","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ehf2.14224","article-title":"Diabetic cardiomyopathy: a brief summary on lipid toxicity","volume":"10","author":"Ke","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.yjmcc.2024.02.009","article-title":"Myocardial glycophagy flux dysregulation and glycogen accumulation characterize diabetic cardiomyopathy","volume":"189","author":"Mellor","year":"2024","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4093\/dmj.2019.0185","article-title":"Mitochondrial mechanisms in diabetic cardiomyopathy","volume":"44","author":"Gollmer","year":"2020","journal-title":"Diabetes Metab. J."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0170","article-title":"The role of renin-angiotensin system in diabetic cardiomyopathy: A Narrative Review","volume":"13","author":"Batista","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0175","doi-asserted-by":"crossref","first-page":"1942086","DOI":"10.1155\/2020\/1942086","article-title":"Calcium homeostasis in ventricular myocytes of diabetic cardiomyopathy","volume":"2020","author":"Al Kury","year":"2020","journal-title":"J. Diabetes Res."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0180","article-title":"Role of oxidative stress in diabetic cardiomyopathy","volume":"11","author":"De Geest","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0185","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221083530","article-title":"Role of inflammation in diabetic cardiomyopathy","volume":"13","author":"Ramesh","year":"2022","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0190","article-title":"Endothelial dysfunction and diabetic cardiomyopathy","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0195","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/CIRCRESAHA.117.312166","article-title":"Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can be modulated by Neuregulin-1","volume":"123","author":"Hopf","year":"2018","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol. Rev."},{"issue":"16","key":"10.1016\/j.yjmcc.2025.06.013_bb0205","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jacc.2009.04.074","article-title":"Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging","volume":"54","author":"Rijzewijk","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0210","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.yjmcc.2025.06.013_bb0215","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2008.07.062","article-title":"Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus","volume":"52","author":"Rijzewijk","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0220","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jacc.2005.09.030","article-title":"Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus","volume":"47","author":"Herrero","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0225","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1111\/j.1464-5491.1991.tb02168.x","article-title":"Myocardial metabolism in type 1 diabetic patients without coronary artery disease","volume":"8","author":"Doria","year":"1991","journal-title":"Diabet. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0230","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1530\/JME-16-0249","article-title":"Lipid metabolism and its implications for type 1 diabetes-associated cardiomyopathy","volume":"58","author":"Ritchie","year":"2017","journal-title":"J. Mol. Endocrinol."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0235","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1172\/JCI10947","article-title":"A novel mouse model of lipotoxic cardiomyopathy","volume":"107","author":"Chiu","year":"2001","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1172\/JCI16751","article-title":"Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy","volume":"111","author":"Yagyu","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0245","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.bbalip.2016.02.011","article-title":"Lipotoxicity in obesity and diabetes-related cardiac dysfunction","volume":"1861","author":"Zlobine","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"24","key":"10.1016\/j.yjmcc.2025.06.013_bb0250","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/01.CIR.0000072789.89096.10","article-title":"Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 Diabetes","volume":"107","author":"Scheuermann-Freestone","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0255","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S0735-1097(03)00625-9","article-title":"Diastolic dysfunction is associatedwith altered myocardial metabolism inasymptomatic normotensive patientswith well-controlled type 2 diabetes mellitus","volume":"42","author":"Diamant","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"10.1016\/j.yjmcc.2025.06.013_bb0260","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.jacc.2009.07.031","article-title":"Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart","volume":"54","author":"Anderson","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.06.013_bb0265","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic Complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0270","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCRESAHA.124.323800","article-title":"Mitochondrial structure and function in human heart failure","volume":"135","author":"Hinton","year":"2024","journal-title":"Circ. Res."},{"issue":"9","key":"10.1016\/j.yjmcc.2025.06.013_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094798","article-title":"Impact of obesity-induced inflammation on cardiovascular diseases (CVD)","volume":"22","author":"Battineni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0280","doi-asserted-by":"crossref","first-page":"1032268","DOI":"10.3389\/fendo.2022.1032268","article-title":"Diabetic cardiomyopathy: clinical phenotype and practice","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0285","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0290","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.2337\/dc23-0931","article-title":"Association between atrial fibrillation and diabetes-related complications: a nationwide cohort study","volume":"46","author":"Kwon","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0295","first-page":"143","article-title":"Association of Atrial Fibrillation with Diabetes mellitus, high risk comorbidities","volume":"17","author":"Ph","year":"2022","journal-title":"Maedica (Bucur)"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0300","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004001","article-title":"Association of early adult modifiable cardiovascular risk factors with left atrial size over a 20-year follow-up period: the CARDIA study","volume":"4","author":"Armstrong","year":"2014","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0305","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.2337\/dc22-0717","article-title":"Associations of new-onset atrial fibrillation with risks of cardiovascular disease, chronic kidney disease, and mortality among patients with type 2 Diabetes","volume":"45","author":"Geng","year":"2022","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0310","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/CIRCULATIONAHA.111.019935","article-title":"Management of Atrial Fibrillation in patients with structural heart disease","volume":"125","author":"Darby","year":"2012","journal-title":"Circulation"},{"issue":"39","key":"10.1016\/j.yjmcc.2025.06.013_bb0315","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0320","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009427","article-title":"Reference ranges for NT-proBNP (N-terminal pro-B-type natriuretic peptide) and risk factors for higher NT-proBNP concentrations in a large general population cohort","volume":"15","author":"Welsh","year":"2022","journal-title":"Circ. Heart Fail."},{"issue":"Suppl. 1","key":"10.1016\/j.yjmcc.2025.06.013_bb0325","first-page":"S179","article-title":"American Diabetes Association professional practice, 10. Cardiovascular disease and risk management: standards of Care in Diabetes-2024","volume":"47","author":"C.","year":"2024","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0330","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.2337\/dc19-0587","article-title":"Machine learning to predict the risk of incident heart failure hospitalization among patients with Diabetes: the WATCH-DM risk score","volume":"42","author":"Segar","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchf.2020.10.013","article-title":"Biomarker-based risk prediction of incident heart failure in pre-Diabetes and Diabetes","volume":"9","author":"Pandey","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"18","key":"10.1016\/j.yjmcc.2025.06.013_bb0340","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0345","article-title":"Role of echocardiography in diabetic cardiomyopathy: from mechanisms to clinical practice","volume":"10","author":"Urlic","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0350","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12933-017-0506-x","article-title":"Diagnostic approaches for diabetic cardiomyopathy","volume":"16","author":"Lorenzo-Almoros","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0355","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/ejhf.2575","article-title":"Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the heart failure Association of the European Society of cardiology","volume":"24","author":"Seferovic","year":"2022","journal-title":"Eur. J. Heart Fail."},{"issue":"1\u20132","key":"10.1016\/j.yjmcc.2025.06.013_bb0360","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1900\/RDS.2015.12.159","article-title":"Biomarkers in diabetic retinopathy","volume":"12","author":"Jenkins","year":"2015","journal-title":"Rev. Diabet. Stud."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0365","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ecl.2021.05.005","article-title":"Prevention of microvascular Complications of Diabetes","volume":"50","author":"Crasto","year":"2021","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0370","series-title":"Precision Medicine in Diabetes: A Multidisciplinary Approach to an Emerging Paradigm","first-page":"1","article-title":"Precision medicine approaches for Management of Type 2 Diabetes","author":"Chen","year":"2022"},{"issue":"9600","key":"10.1016\/j.yjmcc.2025.06.013_bb0375","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.yjmcc.2025.06.013_bb0380","first-page":"S158","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes\u20142024","volume":"47","author":"A.D.A.P.P. Committee","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0385","doi-asserted-by":"crossref","first-page":"1145587","DOI":"10.3389\/fphar.2023.1145587","article-title":"Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0390","article-title":"The ketogenic effect of SGLT-2 inhibitors-beneficial or harmful?","volume":"10","author":"Koutentakis","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"issue":"Supplement_1","key":"10.1016\/j.yjmcc.2025.06.013_bb0395","doi-asserted-by":"crossref","DOI":"10.2337\/db24-33-OR","article-title":"33-OR: the risk of heart failure hospitalization after initiation of SGLT2i, GLP-1RA, DPP-4i, or SUs in patients with type 2 Diabetes and low-to-moderate CV risk","volume":"73","author":"Tesfaye","year":"2024","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0400","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.06.013_bb0405","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 Diabetes: analyses from the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0410","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","article-title":"Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and Diabetes","volume":"10","author":"Filippatos","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"25","key":"10.1016\/j.yjmcc.2025.06.013_bb0415","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Complications study research, intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.yjmcc.2025.06.013_bb0420","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-015-0285-1","article-title":"HbA1c below 7% as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis","volume":"14","author":"Wang","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1297\/cpe.30.1","article-title":"Time in range centered diabetes care","volume":"30","author":"Dovc","year":"2021","journal-title":"Clin. Pediatr. Endocrinol."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0435","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/19322968211049783","article-title":"Patient demographics and clinical outcomes among type 1 Diabetes patients using continuous glucose monitors: data from T1D exchange real-world observational study","volume":"17","author":"DeSalvo","year":"2023","journal-title":"J. Diabetes Sci. Technol."},{"issue":"5","key":"10.1016\/j.yjmcc.2025.06.013_bb0440","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/dia.2019.0417","article-title":"The efficacy of Technology in Type 1 Diabetes: a systematic review, network Meta-analysis, and narrative synthesis","volume":"22","author":"Pease","year":"2020","journal-title":"Diabetes Technol. Ther."},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0445","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0450","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2337\/dc20-1862","article-title":"Time in range in relation to all-cause and cardiovascular mortality in patients with type 2 Diabetes: a prospective cohort study","volume":"44","author":"Lu","year":"2021","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.06.013_bb0455","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/dia.2023.0141","article-title":"The Association of Time in range and diabetic Complications: the evidence is strong","volume":"25","author":"Beck","year":"2023","journal-title":"Diabetes Technol. Ther."},{"issue":"22","key":"10.1016\/j.yjmcc.2025.06.013_bb0460","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0465","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.yjmcc.2025.06.013_bb0470","first-page":"1881","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"Reply, N Engl J Med"},{"issue":"10166","key":"10.1016\/j.yjmcc.2025.06.013_bb0475","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0480","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0485","doi-asserted-by":"crossref","first-page":"4775","DOI":"10.2147\/DDDT.S269514","article-title":"SGLT2 inhibitors: a novel player in the treatment and prevention of diabetic cardiomyopathy","volume":"14","author":"Li","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"24","key":"10.1016\/j.yjmcc.2025.06.013_bb0490","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.yjmcc.2025.06.013_bb0495","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0500","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa2200436","article-title":"Glycemia reduction in type 2 Diabetes - microvascular and cardiovascular outcomes","volume":"387","author":"Nathan","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"9131","key":"10.1016\/j.yjmcc.2025.06.013_bb0505","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"10448","key":"10.1016\/j.yjmcc.2025.06.013_bb0510","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.yjmcc.2025.06.013_bb0515","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"19","key":"10.1016\/j.yjmcc.2025.06.013_bb0520","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1111\/jcmm.17519","article-title":"Protective effects of metformin in various cardiovascular diseases: clinical evidence and AMPK-dependent mechanisms","volume":"26","author":"Bu","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/biom11121834","article-title":"Effects of metformin in heart failure: from pathophysiological rationale to clinical evidence","volume":"11","author":"Salvatore","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0530","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-020-01100-w","article-title":"Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis","volume":"19","author":"Halabi","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0535","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2213-8587(19)30422-X","article-title":"Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map","volume":"8","author":"Zhu","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0540","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"issue":"23","key":"10.1016\/j.yjmcc.2025.06.013_bb0545","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.yjmcc.2025.06.013_bb0550","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with Finerenone in kidney disease and type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0555","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11883-019-0800-z","article-title":"Statins in the prevention and treatment of heart failure: a review of the evidence","volume":"21","author":"Lee","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0560","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a Meta-analysis of 35 randomized controlled trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0565","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019323","volume":"10","author":"Hoskuldsdottir","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"10449","key":"10.1016\/j.yjmcc.2025.06.013_bb0570","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(24)01028-6","article-title":"Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial","volume":"404","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.yjmcc.2025.06.013_bb0575","article-title":"Empagliflozin in heart failure with a preserved ejection fraction. Reply","volume":"386","author":"Anker","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2025.06.013_bb0580","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0585","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.012437","article-title":"Finerenone improves outcomes in patients with heart failure with mildly reduced or preserved ejection fraction irrespective of age: a Prespecified analysis of FINEARTS-HF","volume":"17","author":"Chimura","year":"2024","journal-title":"Circ. Heart Fail."},{"issue":"22","key":"10.1016\/j.yjmcc.2025.06.013_bb0590","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jacc.2023.09.811","article-title":"Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction","volume":"82","author":"Butler","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.yjmcc.2025.06.013_bb0595","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.yjmcc.2025.06.013_bb0600","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0605","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12916-014-0261-8","article-title":"Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials","volume":"13","author":"Chen","year":"2015","journal-title":"BMC Med."},{"issue":"9386","key":"10.1016\/j.yjmcc.2025.06.013_bb0610","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Committees, effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.yjmcc.2025.06.013_bb0615","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Committees angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0620","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.jacc.2021.01.030","article-title":"Cardiac rehabilitation for patients with heart failure: JACC expert panel","volume":"77","author":"Bozkurt","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0625","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Investigators, Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10437","key":"10.1016\/j.yjmcc.2025.06.013_bb0630","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Investigators, Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.yjmcc.2025.06.013_bb0635","doi-asserted-by":"crossref","first-page":"i127","DOI":"10.1093\/eurheartjsupp\/suae011","article-title":"Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction","volume":"26","author":"Temporelli","year":"2024","journal-title":"Eur. Heart J. Suppl."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0640","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a Meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0645","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2009.11.007","article-title":"The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis","volume":"16","author":"Shah","year":"2010","journal-title":"J. Card. Fail."},{"issue":"10367","key":"10.1016\/j.yjmcc.2025.06.013_bb0650","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.06.013_bb0655","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/CIRCULATIONAHA.120.052926","article-title":"How should we sequence the treatments for heart failure and a reduced ejection fraction?","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0660","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5694\/mja2.51656","article-title":"Consensus statement on the current pharmacological prevention and management of heart failure","volume":"217","author":"Sindone","year":"2022","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0665","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2021.18","article-title":"The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction","volume":"7","author":"Brownell","year":"2021","journal-title":"Card. Fail. Rev."},{"issue":"10166","key":"10.1016\/j.yjmcc.2025.06.013_bb0670","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.yjmcc.2025.06.013_bb0675","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Committees, angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.yjmcc.2025.06.013_bb0680","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0685","author":"Nicolas","year":"2024"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0690","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.f55","article-title":"Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis","volume":"346","author":"Chatterjee","year":"2013","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.06.013_bb0695","article-title":"The use of beta-blockers in heart failure with reduced ejection fraction","volume":"8","author":"Masarone","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0700","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12872-016-0425-x","article-title":"Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis","volume":"16","author":"Berbenetz","year":"2016","journal-title":"BMC Cardiovasc. Disord."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0705","first-page":"973","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction. Reply","volume":"382","author":"McMurray","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.yjmcc.2025.06.013_bb0710","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0715","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/ehf2.14310","article-title":"Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis","volume":"10","author":"Salah","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.yjmcc.2025.06.013_bb0720","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for Iron deficiency in patients with heart failure","volume":"79","author":"Masini","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.yjmcc.2025.06.013_bb0725","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.yjmcc.2025.06.013_bb0730","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.yjmcc.2025.06.013_bb0735","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.yjmcc.2025.06.013_bb0740","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jacc.2017.12.024","article-title":"Coronary artery bypass surgery improves outcomes in patients with Diabetes and left ventricular dysfunction","volume":"71","author":"Nagendran","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0745","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.jacc.2020.06.052","article-title":"Long-term survival after surgical or percutaneous revascularization in patients with Diabetes and multivessel coronary disease","volume":"76","author":"Tam","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0750","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11897-022-00548-z","article-title":"Digital technologies to support better outcome and experience of Care in Patients with heart failure","volume":"19","author":"McBeath","year":"2022","journal-title":"Curr. Heart Fail. Rep."},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0755","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10741-019-09801-5","article-title":"Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials","volume":"25","author":"Zhu","year":"2020","journal-title":"Heart Fail. Rev."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0760","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MS9.0000000000002857","article-title":"Advances in diabetic cardiomyopathy: current and potential management strategies and emerging biomarkers","volume":"87","author":"Hassooni","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"issue":"10","key":"10.1016\/j.yjmcc.2025.06.013_bb0765","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with Canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.yjmcc.2025.06.013_bb0770","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with Canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0775","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12967-016-0849-1","article-title":"Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy","volume":"14","author":"Zhang","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0780","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2840-2-16","article-title":"Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study","volume":"2","author":"Rosano","year":"2003","journal-title":"Cardiovasc. Diabetol."},{"issue":"15","key":"10.1016\/j.yjmcc.2025.06.013_bb0785","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1136\/heartjnl-2017-312865","article-title":"Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?","volume":"104","author":"Hutchings","year":"2018","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0790","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/ejhf.711","article-title":"Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes","volume":"19","author":"Matyas","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"19","key":"10.1016\/j.yjmcc.2025.06.013_bb0795","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/CIRCULATIONAHA.111.063412","article-title":"Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy: a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging","volume":"125","author":"Giannetta","year":"2012","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.yjmcc.2025.06.013_bb0800","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1161\/CIRCULATIONAHA.114.012285","article-title":"Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor \u03b1","volume":"131","author":"Liu","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.yjmcc.2025.06.013_bb0805","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI60329","article-title":"Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice","volume":"122","author":"Battiprolu","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"18","key":"10.1016\/j.yjmcc.2025.06.013_bb0810","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.166713","article-title":"Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose","volume":"8","author":"Li","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0815","doi-asserted-by":"crossref","first-page":"1124613","DOI":"10.3389\/fendo.2023.1124613","article-title":"Diabetic cardiomyopathy: the role of microRNAs and long non-coding RNAs","volume":"14","author":"Macvanin","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.yjmcc.2025.06.013_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/cells11020240","article-title":"Mesenchymal stem cell therapy in diabetic cardiomyopathy","volume":"11","author":"da Silva","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.yjmcc.2025.06.013_bb0825","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13287-020-01633-7","article-title":"Mesenchymal stem cells ameliorate myocardial fibrosis in diabetic cardiomyopathy via the secretion of prostaglandin E2","volume":"11","author":"Jin","year":"2020","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.yjmcc.2025.06.013_bb0830","author":"Australian Medicines Handbook"},{"issue":"19","key":"10.1016\/j.yjmcc.2025.06.013_bb0835","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Investigators, Semaglutide and cardiovascular outcomes in patients with type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282825001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282825001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T16:51:45Z","timestamp":1756745505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282825001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":167,"alternative-id":["S0022282825001117"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2025.06.013","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2025.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}